/solarbytes/media/media_files/2025/02/05/LKGlYknxmGfAQp7pZ1Gz.jpeg)
The Lorca Solar project, expected to begin operations in early 2026, will supply clean energy to pharmaceutical companies through a VPPA agreement. Image Source: X-ELIO
X-ELIO, headquartered in Spain, has signed a multi-buyer Power Purchase Agreement with four pharmaceutical companies under the Energize program. Thermo Fisher Scientific, Haleon, Gilead Sciences, and GSK will purchase 245 GWh of renewable energy annually for a decade. The energy will be sourced from X-ELIO’s 369 MW Lorca Solar project which is expected to begin operations by early 2026. X-ELIO has integrated social and local responsibility into the Lorca Solar project through a Community Plan. The VPPA, part of the Energize program, a supply chain renewables initiative designed and delivered by Schneider Electric, is endorsed by PSCI and X-ELIO. The PSCI initiative aligns with efforts to support the pharmaceutical sector’s supply chain decarbonization.